A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea

Inclusion Criteria: * Subjects must be \>=6 or ≦80 years of age at the time of signing the informed consent,both gender * Subjects having clinical suspicion of a urogenital gonococcal infection with or without gonococcal infection according to the laboratory test results of symptoms, physical symptoms, gonococcus smear, culture, etc. * Subjects having clinical suspicion of a gonococcal infection must have both of the following risk factors:once used three generations of cephalosporin invalid, and sensitive to this product (including gonorrhea urethritis, cervicitis, proctitis, pharyngitis). * Male and female subject must agree to use contraception (male condoms) during intercourse from the Baseline Visit through completion of the TOC Visit. Exclusion Criteria: * Subject has a history of sensitivity to the study treatments, or components thereof, or a history of a drug (including erythromycin and any macrolide or ketolide drug) or other allergy that, in the opinion of the investigator or medical monitor, contraindicates his or her participation * Subject has received any cephalosporinl therapy for the treatment of a gonococcal infection * Pregnant or lactating women, or women Subject of childbearing age who were unwilling or unable to use acceptable methods of contraception throughout the study period. * Famale subject who were positive for pregnancy tests at the time of inclusion or before the start of study drug use. * Subject has risk of potentially serious drug interactions * Subject has major diseases such as cardiovascular disease, hepatorenal disease and mental disease, or other factors, the researcher should not participate in the study according to comprehensive judgment * Subject has a known history of alcohol or drug abuse * Subject has a known any complicated or systemic gonorrhea infection, such as pelvic inflammatory disease, arthritis, endocarditis